745 related articles for article (PubMed ID: 18649770)
1. [Effects of valsartan, mycophenolate mofetil and their combined application on TRAIL and nuclear factor-kappaB expression in the kidneys of diabetic rats].
Chen B; Zhang Y; Liu G; Guan GJ; Hou XH; Li XG; Liu JL
Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(8):540-5. PubMed ID: 18649770
[TBL] [Abstract][Full Text] [Related]
2. Effects of mycophenolate mofetil, valsartan and their combined therapy on preventing podocyte loss in early stage of diabetic nephropathy in rats.
Zhang Y; Chen B; Hou XH; Guan GJ; Liu G; Liu HY; Li XG
Chin Med J (Engl); 2007 Jun; 120(11):988-95. PubMed ID: 17624267
[TBL] [Abstract][Full Text] [Related]
3. Experimental study of leflunomide on renal protective effect and on inflammatory response of streptozotocin induced diabetic rats.
Yu WM; Wang H; Ren XJ; Liu JP; Wang JY
Nephrology (Carlton); 2012 May; 17(4):380-9. PubMed ID: 22243699
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolate mofetil and valsartan inhibit podocyte apoptosis in streptozotocin-induced diabetic rats.
Lv W; Zhang Y; Guan G; Li P; Wang J; Qi D
Pharmacology; 2013; 92(3-4):227-34. PubMed ID: 24158161
[TBL] [Abstract][Full Text] [Related]
5. [Effects of quercetin on nuclear factor-κB p65 expression in renal ubiquitin-proteasome system of diabetic rats].
Chen P; Chen JB; Chen WY; Zheng QL; Wang YQ; Xu XJ
Zhonghua Nei Ke Za Zhi; 2012 Jun; 51(6):460-5. PubMed ID: 22943758
[TBL] [Abstract][Full Text] [Related]
6. [Activation of transforming growth factor-beta1/Smads signal pathway in diabetic cardiomyopathy and effects of valsartan thereon: experiment with rats].
Miao Y; Zhang W; Zhong M; Ma X; Qi TG; Sun H
Zhonghua Yi Xue Za Zhi; 2007 Feb; 87(6):366-70. PubMed ID: 17456374
[TBL] [Abstract][Full Text] [Related]
7. [Mechanism of reversion of myocardial interstitial fibrosis in diabetic cardiomyopathy by valsartan].
Zhong M; Zhang Y; Miao Y; Li L; Gong HP; Ma X; Sun H; Zhang W
Zhonghua Yi Xue Za Zhi; 2006 Jan; 86(4):232-6. PubMed ID: 16677501
[TBL] [Abstract][Full Text] [Related]
8. Renoprotective effects of valsartan and enalapril in STZ-induced diabetes in rats.
Kalender B; Oztürk M; Tunçdemir M; Uysal O; Dagistanli FK; Yegenaga I; Erek E
Acta Histochem; 2002; 104(2):123-30. PubMed ID: 12086332
[TBL] [Abstract][Full Text] [Related]
9. Valsartan inhibited HIF-1α pathway and attenuated renal interstitial fibrosis in streptozotocin-diabetic rats.
Tang L; Yi R; Yang B; Li H; Chen H; Liu Z
Diabetes Res Clin Pract; 2012 Jul; 97(1):125-31. PubMed ID: 22377232
[TBL] [Abstract][Full Text] [Related]
10. [Relationship between activation of mannan-binding lectin complement and NF-kappaB in diabetic nephropathy].
Yang YX; Huang SM; Yan XY; Wu WH
Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Jul; 42(4):490-3. PubMed ID: 21866632
[TBL] [Abstract][Full Text] [Related]
11. [Protective effect of astragalus saponin extracts on kidneys of diabetic rats].
Xiao F; Hu YG; Wu SN; Shou QY; Cai YQ; Wang HM; Wang H
Zhongguo Zhong Yao Za Zhi; 2015 May; 40(10):2014-8. PubMed ID: 26390666
[TBL] [Abstract][Full Text] [Related]
12. BAY 11-7082 ameliorates diabetic nephropathy by attenuating hyperglycemia-mediated oxidative stress and renal inflammation via NF-κB pathway.
Kolati SR; Kasala ER; Bodduluru LN; Mahareddy JR; Uppulapu SK; Gogoi R; Barua CC; Lahkar M
Environ Toxicol Pharmacol; 2015 Mar; 39(2):690-9. PubMed ID: 25704036
[TBL] [Abstract][Full Text] [Related]
13. [Impact of glycogen synthase kinase-3β (GSK-3β) inhibitor on Wnt and NF-κB signal pathways in a rat model of diabetic nephropathy].
Zhou Y; Li L; Yu Y; Yang H; Yao H; Zhang Y; Zhang L; Deng C; Zhao L; Zhang Y; Song B
Zhonghua Bing Li Xue Za Zhi; 2015 Nov; 44(11):783-7. PubMed ID: 26888388
[TBL] [Abstract][Full Text] [Related]
14. Local delivery of angiotensin II receptor blockers into the kidney passively attenuates inflammatory reactions during the early phases of streptozotocin-induced diabetic nephropathy through inhibition of calpain activity.
Kamal F; Yanakieva-Georgieva N; Piao H; Morioka T; Oite T
Nephron Exp Nephrol; 2010; 115(3):e69-79. PubMed ID: 20424485
[TBL] [Abstract][Full Text] [Related]
15. Mycophenolate mofetil ameliorates diabetic nephropathy through epithelial mesenchymal transition in rats.
Xiao X; Wang J; Chang X; Zhen J; Zhou G; Hu Z
Mol Med Rep; 2015 Sep; 12(3):4043-4050. PubMed ID: 26080907
[TBL] [Abstract][Full Text] [Related]
16. Irbesartan ameliorates diabetic nephropathy by reducing the expression of connective tissue growth factor and alpha-smooth-muscle actin in the tubulointerstitium of diabetic rats.
Ren X; Guan G; Liu G; Liu G
Pharmacology; 2009; 83(2):80-7. PubMed ID: 19065061
[TBL] [Abstract][Full Text] [Related]
17. Combined MMF and insulin therapy prevents renal injury in experimental diabetic rats.
Wu X; Zha D; Xiang G; Zhang B; Xiao SY; Jia R
Cytokine; 2006 Dec; 36(5-6):229-36. PubMed ID: 17337203
[TBL] [Abstract][Full Text] [Related]
18. [Effects of lovastatin on renal function and expression of phosphorylating-p38 mitogen-activated protein kinase in experimental diabetic nephropathy in rats].
Wang LH; Duan HJ; Shi YH; Liu QJ; He N; Liu SX
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2004 Dec; 16(12):734-7. PubMed ID: 15585148
[TBL] [Abstract][Full Text] [Related]
19. Combination of leflunomide and benazepril reduces renal injury of diabetic nephropathy rats and inhibits high-glucose induced cell apoptosis through regulation of NF-κB, TGF-β and TRPC6.
Li H; Wang Y; Zhou Z; Tian F; Yang H; Yan J
Ren Fail; 2019 Nov; 41(1):899-906. PubMed ID: 31552773
[No Abstract] [Full Text] [Related]
20. Prevention of early renal injury by mycophenolate mofetil and its mechanism in experimental diabetes.
Wu YG; Lin H; Qi XM; Wu GZ; Qian H; Zhao M; Shen JJ; Lin ST
Int Immunopharmacol; 2006 Mar; 6(3):445-53. PubMed ID: 16428080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
